Results 101 to 110 of about 276,101 (206)

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Advanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer, Ian de Ridder, Mahjoobeh Ehsani, Marasim Khan, Justin Kale, Lukas P. Frenzel, David Andrews, Spyridoula Karamanou, Ana J. Garcia‐Saez, Geert Bultynck   +9 more
wiley   +1 more source

A High‐Loading Zn Single‐Atom Nanozyme Targets the Zn/HIF‐1α/GLUT1 Axis to Disrupt Glucose Metabolic Reprogramming and Remodel the Tumor Immune Microenvironment

Advanced Science, EarlyView.
A high‐loading Zn single‐atom nanozyme (ZMG@CS) delivers ML‐SA5 and GOx to lysosomes. ML‐SA5 activates TRPML1 to release endogenous Zn2+, while the nanozyme provides exogenous Zn2+ and GOx‐driven acidification amplifies ROS production. Together, these effects suppress the HIF‐1α/GLUT1 axis, disrupt glucose and redox homeostasis, induce disulfidptosis ...
Zhenxin Wang, Yuhang Tang, Ronghao Yue, Jingtao Xu, Yong Tao, Jie Chen, Shipeng Li, Guosheng Zhao, Jinfang Xue, Mingwei Sun, Fenglei Gao, Yunsheng Ou, Yang Wang   +12 more
wiley   +1 more source

Review of Gastrointestinal Capsule Robots: Materials, Actuation, Diagnostics, and Therapeutics

Advanced Science, EarlyView.
This review examines gastrointestinal capsule robots through a systems engineering lens, covering shell materials, actuation and localization strategies, diagnostic modalities, therapeutic interventions, and commercialization status. By mapping the complete technological chain from fabrication to clinical deployment, this work identifies critical gaps ...
Zengsheng Li, Zhongguo Ren, Yiliang Lin, Xianfeng Xia, Tianlong Li, Kai Fung Chan, Philip Wai Yan Chiu, Wei Peng Yong, Mengmeng Sun   +8 more
wiley   +1 more source

A Single‐Amino‐Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome‐Targeted Degradation of Membrane Proteins

Advanced Science, EarlyView.
LA‐LYTAC repurposes the cancer‐enriched amino acid transporter LAT1 as a lysosomal trafficking receptor for targeted membrane‐protein degradation. A single phenylalanine‐derived ligand, modularly linked to antibodies or small‐molecule binders, recruits PD‐L1, EGFR, or integrins to LAT1, triggering transporter‐mediated internalization, lysosomal ...
Liquan Zhu, Ke Liu, Haotian Liu, Chaoqi He, Xiaozhen Liu, Xin Zeng, Misha Mao, Yuxiao Mu, Ying Li, Qinghui Zheng, Hongchao Tang, Da Qian, Xuli Meng   +12 more
wiley   +1 more source

Lanthanum Carbonate Nanosheets Based Colloidal Hydrogel for Modulating Innate & Adaptive Tumor Immunotherapy by Augmented Cellular Pyroptosis

Advanced Science, EarlyView.
The Gela/decitabine/La2(CO3)3 colloidal (GDLC) hydrogel developed here could reverse the epigenetic silencing of the GSDME gene by the synergistic interaction between DAC and La3+, while concurrently activating caspase‐3, thus facilitating pyroptosis induction under the tumor microenvironment.
Yang Hong, Haitao Wu, Weitao Wang, Xuan Zhang, Qian Chen, Yaoyu Hu, Zhengbao Zha   +6 more
wiley   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

Advanced Science, EarlyView.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei, Changning Xue, Mengna Li, Jianxia Wei, Lemei Zheng, Shipeng Chen, Yijie Wang, Yumei Duan, Yanwei Luo, Wei Xiong, Ming Zhou   +10 more
wiley   +1 more source

Abnormal microRNA expression in the course of hematological malignancies

, 2018
Agnieszka Szymczyk,1 Arkadiusz Macheta,2 Monika Podhorecka2 1Independent Clinical Transplantology Unit, Medical University of Lublin, Lublin, Poland; 2Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin ...
Szymczyk A, Podhorecka M, Macheta A
core  

Magneto‐NIR‐II‐Programmed Cascade Nanozymes Unlocking Blood–Brain Barrier Translocation and Autophagic Resistance in Glioblastoma

Advanced Science, EarlyView.
Magneto‐NIR‐II‐programmed NFSH nanozymes integrate magnetic blood–brain barrier (BBB) translocation, CD44 targeting, multimodal imaging, and cascade catalytic therapy for glioblastoma. Alternating magnetic fields and NIR‐II irradiation amplify ferroptosis, release H2S, suppress autophagic and mitophagic repair, and reshape the immune microenvironment ...
Ruocan Liu, Yundi Wu, Shuai Zhang, Hongjuan Zhao, Jiping Zheng, Shiyang Shao, Jianqiang Chen, Xilong Wu   +7 more
wiley   +1 more source

Metabolic Reprogramming in Glioblastoma Stem Cells Promotes Radiation Resistance Through a H3K18la/USP30/MBOAT2 Axis

Advanced Science, EarlyView.
LDHA‐driven lactate production in mesenchymal glioma stem cells promotes p300‐dependent H3K18 lactylation, activates USP30 transcription, and stabilizes MBOAT2 to remodel phosphatidylethanolamines toward ferroptosis‐resistant PE‐MUFA species. Disrupting this metabolic–epigenetic–lipid circuit enhances ferroptosis and sensitizes glioblastoma to ...
Zong Miao, Wei Gu, Yimin Ren, Chenfei Lu, Wanzhi Cai, Junnan Lu, Zhongyuan Bao, Yanan Zhou, Rong Li, Ke Jin, Chao Chen, Hongxiang Wang, Lei Xu, Juxiang Chen   +13 more
wiley   +1 more source

Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
IGF2BP1 promotes gemcitabine resistance in pancreatic cancer by stabilizing m6A‐modified FTH1 transcripts and protecting them in stress granules, thereby suppressing ferroptosis. Pharmacological inhibition of IGF2BP1 disrupts this protective pathway, restores ferroptotic sensitivity, and enhances gemcitabine efficacy in resistant tumors.
Ying‐Qin Zhu, Yue Huang, Jing‐Yuan Ye, Si‐Yuan Lu, Zhi‐De Liu, Ming‐Jian Ma, De‐Liang Fang, Zi‐Yi Zhao, Jin‐Zhao Xie, Jiao Chen, Xiao‐Yu Yin   +10 more
wiley   +1 more source